Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)
The purpose of this study is to compare the gastrointestinal tolerability of an investigational drug to an approved drug in the treatment of osteoarthritis during one year treatment period.
Drug: MK0663, etoricoxib
Drug: Comparator: Diclofenac sodium
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis|
- Discontinuations due to clinical and laboratory gastrointestinal adverse experiences during a 1 year treatment period.
|Study Start Date:||June 2002|
|Study Completion Date:||November 2003|
|Primary Completion Date:||November 2003 (Final data collection date for primary outcome measure)|
The duration of treatment is 12 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00092703
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|